Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

NCT04726553 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

NCT06576102 ·Status: ACTIVE_NOT_RECRUITING

Effect of Anti-CD303 Antibodies in Autoimmune Diseases

NCT03370627 ·Status: COMPLETED ·Phase: NA

Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases

NCT04690816 ·Status: COMPLETED

Immunoadsorption in Autoimmune Long COVID

NCT07316127 ·Status: RECRUITING ·Phase: PHASE2

A Study of RD06-04 in Patients With Active Autoimmune Diseases

NCT06548620 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1

A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus

NCT06900764 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

NCT06041568 ·Status: TERMINATED ·Phase: PHASE1

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285 ·Status: RECRUITING

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

NCT05689463 ·Status: RECRUITING ·Phase: NA

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT05858684 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960 ·Status: RECRUITING ·Phase: PHASE4

Study of Leukocyte Populations in Patients With Chronic Inflammatory

NCT04749875 ·Status: NOT_YET_RECRUITING

Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination

NCT05313048 ·Status: COMPLETED

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

NCT05835986 ·Status: RECRUITING ·Phase: PHASE1

Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases

NCT05383339 ·Status: RECRUITING

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

NCT00423098 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805 ·Status: RECRUITING ·Phase: PHASE2

INFLAMmatory BiomarkErs in COVID-19 Participants and Severity of Disease

NCT05175846 ·Status: UNKNOWN

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

NCT01408576 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Anti-CD20 Antibodies for Treatment of SLE-PAH

NCT05828147 ·Status: RECRUITING ·Phase: PHASE4

An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT04810754 ·Status: UNKNOWN ·Phase: PHASE2